Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
Matthew R WeirJagadish GogateC V DamarajuRicardo Correa-RotterKenneth W MahaffeyPublished in: Diabetes, obesity & metabolism (2021)
Canagliflozin reduced the risk of MACE overall, and among Hispanic participants with T2D and high cardiovascular risk or nephropathy in the CANVAS Program and CREDENCE trial, without heterogeneity by baseline eGFR.
Keyphrases
- cardiovascular events
- phase iii
- coronary artery disease
- clinical trial
- quality improvement
- study protocol
- open label
- phase ii
- small cell lung cancer
- cardiovascular disease
- african american
- epidermal growth factor receptor
- single cell
- double blind
- tyrosine kinase
- placebo controlled
- emergency department
- electronic health record